Patents by Inventor Satyamaheshwar Peddibhotla

Satyamaheshwar Peddibhotla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12103917
    Abstract: Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject.
    Type: Grant
    Filed: June 8, 2021
    Date of Patent: October 1, 2024
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Daniel Kelly, Richard Vega, Hampton Sessions, Teresa Leone, Byungyong Ahn, Satyamaheshwar Peddibhotla
  • Publication number: 20240166614
    Abstract: Various embodiments relate to compounds and methods useful for preventing or treating a cancer in a subject. The method may include administering to a subject a composition according to any of the embodiments described herein in an amount effective to inhibit metastatic activity or tumor growth in the subject.
    Type: Application
    Filed: January 16, 2024
    Publication date: May 23, 2024
    Inventors: Otto PHANSTIEL, IV, Holly MOOTS, Patrick MALONEY, Paul HERSHBERGER, Satyamaheshwar PEDDIBHOTLA
  • Patent number: 11905268
    Abstract: Various embodiments relate to compounds and methods useful for preventing or treating a cancer in a subject. The method may include administering to a subject a composition according to any of the embodiments described herein in an amount effective to inhibit metastatic activity or tumor growth in the subject.
    Type: Grant
    Filed: August 12, 2019
    Date of Patent: February 20, 2024
    Assignees: UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC., SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Otto Phanstiel, IV, Holly Moots, Patrick Maloney, Paul Hershberger, Satyamaheshwar Peddibhotla
  • Publication number: 20230203025
    Abstract: In some embodiments, the present disclosure provides a compound of Formula (I), as described herein, or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions comprising the compound of Formula (I), and methods of treating, e.g., metabolic diseases using the compound of Formula (I) are also provided.
    Type: Application
    Filed: May 28, 2021
    Publication date: June 29, 2023
    Inventors: John C. Burnett, Jr., Jeson Sangaralingham, Siobhan Malany, Satyamaheshwar Peddibhotla, Paul Mitchell Hershberger, Patrick Maloney, Edward Hampton Sessions, Jr.
  • Publication number: 20220402908
    Abstract: Provided herein are small molecule inhibitors of CXCR6 receptor, compositions comprising the compounds, and methods of using the compounds and compositions. The compounds are 9-azbicyclo[3.3.1]nonane or 9-diazbicyclo[3.3.1]nonane derivatives, whose synthesis is also described. Also provided are method of treating a disease or condition (such as, cancer) mediated by CXCR6/CXCL16 signaling pathway in a mammal.
    Type: Application
    Filed: July 7, 2020
    Publication date: December 22, 2022
    Inventors: Satyamaheshwar PEDDIBHOTLA, Paul M. HERSHBERGER, Richard Jason KIRBY, Siobhan MALANY, Layton H. SMITH, Patrick R. MALONEY, Hampton SESSIONS, Daniela DIVLIANSKA, Anthony B. PINKERTON
  • Publication number: 20220064133
    Abstract: A method and apparatus for transferring an image of predetermined length onto a substrate by selective energization of a row of printing elements in a printhead of a printing apparatus. Operational characteristics of the printing apparatus are determined, and the image is rendered such that the number of rows of the pixels in the rendered image is no greater than the maximum number of rows of pixels which can be printed in the length of the image given the operational characteristics of the printing apparatus. Additional rows of pixels may be printed between pairs of rows of printed which correspond to consecutive rows in the rendered image. The pixel content of each additional row is a function of the pixel content of the adjacent pairs of rows.
    Type: Application
    Filed: August 12, 2019
    Publication date: March 3, 2022
    Inventors: Otto PHANSTIEL, IV, Holly MOOTS, Patrick MALONEY, Paul HERSHBERGER, Satyamaheshwar PEDDIBHOTLA
  • Patent number: 11261164
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Grant
    Filed: January 14, 2020
    Date of Patent: March 1, 2022
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Paul M. Hershberger, Satyamaheshwar Peddibhotla, Patrick R. Maloney, Michael P. Hedrick
  • Publication number: 20210300882
    Abstract: Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject.
    Type: Application
    Filed: June 8, 2021
    Publication date: September 30, 2021
    Applicant: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Daniel Kelly, Richard Vega, Hampton Sessions, Teresa Leone, Byungyong Ahn, Satyamaheshwar Peddibhotla
  • Patent number: 11028061
    Abstract: Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: June 8, 2021
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Daniel Kelly, Richard Vega, Hampton Sessions, Teresa Leone, Byungyong Ahn, Satyamaheshwar Peddibhotla
  • Publication number: 20200354324
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Application
    Filed: January 14, 2020
    Publication date: November 12, 2020
    Inventors: Anthony B. PINKERTON, Paul M. HERSHBERGER, Satyamaheshwar PEDDIBHOTLA, Patrick R. MALONEY, Michael P. HEDRICK
  • Patent number: 10584103
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: March 10, 2020
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Paul M. Hershberger, Satyamaheshwar Peddibhotla, Patrick R. Maloney, Michael P. Hedrick
  • Publication number: 20190023665
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Application
    Filed: September 24, 2018
    Publication date: January 24, 2019
    Inventors: Anthony B. PINKERTON, Paul M. HERSHBERGER, Satyamaheshwar PEDDIBHOTLA, Patrick R. MALONEY, Michael P. HEDRICK
  • Patent number: 10118902
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Grant
    Filed: June 24, 2015
    Date of Patent: November 6, 2018
    Assignee: SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
    Inventors: Anthony B. Pinkerton, Paul M. Hershberger, Satyamaheshwar Peddibhotla, Patrick R. Maloney, Michael P. Hedrick
  • Publication number: 20180222874
    Abstract: Formulations and methods for reducing blood glucose and/or increasing insulin signaling in a subject have been developed. The formulations include SBI-477 and compounds based on SBI-477 i.e., SBI-477 analogs (collectively, SBI-477 compounds) and/or Mondo family inhibitors, in an effective amount to inhibit intracellular lipid accumulation and/or increase cellular glucose uptake when compared to levels in a control subject not administered the composition. Also disclosed are methods of reducing intracellular lipid accumulation and/or increase glucose uptake in a subject in need thereof. The method includes administering to the subject an effective amount of SBI-477 compounds and/or Mondo family inhibitor to reducing intracellular lipid accumulation and/or increase glucose uptake in the subject.
    Type: Application
    Filed: July 27, 2016
    Publication date: August 9, 2018
    Applicant: Sanford Bumham Prebys Medical Discovery Imstitute
    Inventors: Daniel Kelly, Richard Vega, Hampton Sessions, Teresa Leone, Byungyong Ahn, Satyamaheshwar Peddibhotla
  • Patent number: 9868707
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Grant
    Filed: December 19, 2013
    Date of Patent: January 16, 2018
    Assignees: SANFORD-BURNHAM MEDICAL RESEARCH INSTITUTE, DUKE UNIVERSITY
    Inventors: Anthony Pinkerton, Patrick Maloney, Paul Hershberger, Satyamaheshwar Peddibhotla, Michael Hedrick, Lawrence Barak, Marc Caron
  • Publication number: 20170240514
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Application
    Filed: June 24, 2015
    Publication date: August 24, 2017
    Inventors: Anthony B. PINKERTON, Paul M. HERSHBERGER, Satyamaheshwar PEDDIBHOTLA, Patrick R. MALONEY, Michael P. HEDRICK
  • Publication number: 20150329497
    Abstract: Provided herein are small molecule neurotensin receptor agonists, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
    Type: Application
    Filed: December 19, 2013
    Publication date: November 19, 2015
    Applicant: DUKE UNIVERSITY
    Inventors: Anthony PINKERTON, Patrick MALONEY, Paul HERSHBERGER, Satyamaheshwar PEDDIBHOTLA, Michael HEDRICK, Lawrence BARAK, Marc CARON
  • Patent number: 7858808
    Abstract: A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc.), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-?B as well as potent activity against the Gram (+) bacterium B. subtillus and B. cereus with MIC values in the range of 50 ?m/mL.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: December 28, 2010
    Assignee: Board of Trustees of Michigan State University
    Inventors: Jetze J. Tepe, Satyamaheshwar Peddibhotla
  • Publication number: 20100204260
    Abstract: A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc.), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-?B as well as potent activity against the Gram (+) bacterium B. subtillus and B. cereus with MIC values in the range of 50 ?m/mL.
    Type: Application
    Filed: January 26, 2010
    Publication date: August 12, 2010
    Inventors: Jetze J. Tepe, Satyamaheshwar Peddibhotla
  • Patent number: 7652056
    Abstract: A new class of imidazolines as 4-position acids or esters with very potent anti-inflammatory as well as antimicrobial activity is described. The synthesis of these imidazolines includes a multicomponent reaction applicable to a combinatorial synthetic approach. The combination of these two key characteristics provides an effective therapeutic drug in the treatment of septic shock as well as many other inflammatory (arthritis and asthma) and infectious disorders. The use of this novel class of non-steroidal agents as anti-inflammatory agents (for the treatment of asthma etc.), antibacterial agents and antiseptic agents is described. The compounds are also useful in the treatment of tumors (such as cancers). The imidazolines are potent inhibitors of the transcription factor NF-?B as well as potent activity against the Gram (+) bacterium B. subtillus and B. cereus with MIC values in the range of 50 ?m/mL.
    Type: Grant
    Filed: April 6, 2005
    Date of Patent: January 26, 2010
    Assignee: Board of Trustees of Michigan State University
    Inventors: Jetze J. Tepe, Satyamaheshwar Peddibhotla